Πίσω
Πίσω

Day 3

73 A. Kamat - Viewpoint of Urologist

73 A. Kamat - Viewpoint of Urologist

74 N. James - Viewpoint of Radiation Oncologist

74 N. James - Viewpoint of Radiation Oncologist

75 S. Gupta - Viewpoint of Medical Oncologist

75 S. Gupta - Viewpoint of Medical Oncologist

76 Q & As

76 Q & As

77 K. Oualla - Unmet needs and global perspectives in histologic subtypes of bladder cancer

77 K. Oualla - Unmet needs and global perspectives in histol...

78 V. Tzelepi - Pathology approach: Re defining ncc-RCC: updated classification

78 V. Tzelepi - Pathology approach: Re defining ncc-RCC: upd...

79 M.O. Timsit - - Viewpoint of Urologist

79 M.O. Timsit - - Viewpoint of Urologist

80 K. Oualla - Viewpoint of Medical Oncologist

80 K. Oualla - Viewpoint of Medical Oncologist

81 Q & As

81 Q & As

82 M.T. Bourlon - Disparities in the management and outcomes in kidney cancer

82 M.T. Bourlon - Disparities in the management and outcomes...

83 S. Gupta  - Global perspective and disparities in the management of bladder cancer

83 S. Gupta - Global perspective and disparities in the mana...

84 Q & As

84 Q & As

85 Th. Pappa - Recent updates in the management of endocrine malignancies

85 Th. Pappa - Recent updates in the management of endocrine...

86 K. Xynos - Oncolytic viruses in the treatment of cancer

86 K. Xynos - Oncolytic viruses in the treatment of cancer

87 V. Subbiah - Lessons learned from building phase I programs

87 V. Subbiah - Lessons learned from building phase I progra...